Joincare Pharmaceutical group updates governance, board

Joincare Pharmaceutical Group Industry (SSE:600380) held its second extraordinary general meeting of shareholders on November 14, 2025, passing several key resolutions. Shareholders approved the cancellation of the supervisory board, changes to the registered capital, and amendments to the company's articles of association. The registered capital was adjusted to RMB 1,829,453,386.

Concurrently, the company elected Ms. Yang Ying as the new employee representative director for the ninth board of directors, serving a three-year term. Ms. Yang Ying holds a master's degree in clinical medicine and has extensive experience in clinical research, medical affairs, drug vigilance, and quality assurance. This change is in line with the revised articles of association, which now stipulate a ten-member board, including one employee director, and ensure that the number of executive directors and employee representatives does not exceed half of the total board.

Further updates include revisions to the board of directors' rules of procedure, shareholders' meeting rules of procedure, independent directors' work system, related party transaction management system, and fund-raising management system. These revisions align the company’s governance with current legal frameworks and internal operational requirements, enhancing decision-making and oversight. The company confirmed that there were no denied proposals during the meeting.